ACRV
Acrivon Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.57 / 10
Outperform
Analyst coverage is limited to one Buy from Piper Sandler, with a 100% historical win rate. Fund‑flow score is 7.59/10 (good); large investors show positive inflow (ratio 0.511), while other segments are negative. Overall sentiment leans bullish.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionPiper Sandler
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for ACRV?
- ACRV holds a Bullish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.57/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
